A review of studies of the Montgomery???Asberg Depression Rating Scale in controls: implications for the definition of remission in treatment studies of depression
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The Montgomery-Asberg Depression Rating Scale (MADRS) is one of the most commonly used symptom severity scales to evaluate the efficacy of antidepressant treatment Various cut-offs have been employed in antidepressant efficacy trials to define remission, although little empirical work has been carried out to determine the validity of various thresholds. One approach towards deriving a valid cut-off score for defining remission is to determine whether a patient's level of symptoms falls within the normal range of values after treatment We therefore conducted a literature review of studies of the MADRS in healthy controls to determine the normal range of values. We identified 10 studies of 14 samples that included data on the MADRS for 569 controls. Across all studies, the mean (+/- SD) weighted MADRS score, adjusting for sample size, was 4.0 (5.8) (95% confidence interval 3.5-4.5). These results are consistent with the findings of our study of the validity of different cut-offs to define remission on the MADRS-based on a narrow definition of remission, which required a complete absence of clinically significant symptoms of depression, the optimal MADRS cut-off was < or = 4 whereas based on a broader definition, the optimal cut-off was < or = 9. The findings can be used for normative comparisons in which post-treatment group mean scores are compared to mean scores from normative samples. A limitation of the review is that none of the studies was based on a randomly selected sample from the general population. In addition, the rigor of the screening used to exclude individuals with psychopathology in most studies is unknown; thus, some of the controls may have had diagnosable depression, thereby elevating the mean scores in the presumptively healthy control group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jacobson, N. S., & Truax, P. (1991) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.59.1.12 · Cited by 7,770
(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · cited 1×
“Following the publication of the recommendations of Frank et al. (1991), a consensus has emerged to define remission on the HRSD as a score of 7 or less, although alternative thresholds continue to be used (Berk et al., 1997; Schweizer et al., 2001; Taragano et al., 2001; Trivedi et al., 2001).”
BackgroundInfluentialCytokine Production and Treatment Response in Major Depressive Disorder
Lanquillon, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00134-7 · Cited by 735
Residual symptoms in depressed patients who respond acutely to fluoxetine
Nierenberg, A. A., Keefe, B. R., Leslie, V. C., Alpert, J. E., Pava, J. A., Worthington, J. J., Rosenbaum, J. F., & Fava, M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0403 · Cited by 470
Keller, M. B. (2003) · JAMA · doi:10.1001/jama.289.23.3152 · Cited by 388 · cited 1×
“As recently noted by Keller (2003) in a review of issues related to assessing outcome in depression, in the absence of biological state markers of depressive illness, the course of the disorder and the outcome of treatment must be assessed indirectly with interview and questionnaire measures of…”
BackgroundVenlafaxine for Treatment-Resistant Unipolar Depression
NIERENBERG, A. A., FEIGHNER, J. P., RUDOLPH, R., COLE, J. O., & SULLIVAN, J. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199412000-00008 · Cited by 198
Mirtazapine Versus Venlafaxine in Hospitalized Severely Depressed Patients With Melancholic Features
Guelfi, J. D., Ansseau, M., Timmerman, L., & Kørsgaard, S. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200108000-00010 · Cited by 138
Taragano, F. E., Allegri, R., Vicario, A., Bagnatti, P., & Lyketsos, C. G. (2001) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.340 · Cited by 103 · cited 2×
“(1991), a consensus has emerged to define remission on the HRSD as a score of 7 or less, although alternative thresholds continue to be used (Berk et al., 1997; Schweizer et al., 2001; Taragano et al., 2001; Trivedi et al., 2001).”
BackgroundInfluentialMontgomery-Åsberg severity gradations
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.9.1320b · Cited by 39 · cited 1×
“Mittmann et al. (1997) conducted a regression analysis to derive a formula for equating MADRS and HRSD scores, and found that a MADRS cut-off r 8 was equivalent to the HRSD remission definition of r 7.”
Method
Cited by
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707
Tohen, M., Frank, E., Bowden, C. L., Colom, F., Ghaemi, S. N., Yatham, L. N., Malhi, G. S., Calabrese, J. R., Nolen, W. A., Vieta, E., et al. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00726.x · Cited by 513
Sjöberg, L., Karlsson, B., Atti, A.-R., Skoog, I., Fratiglioni, L., & Wang, H.-X. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.06.011 · Cited by 269
Tolin, D. F., Frost, R. O., Steketee, G., & Muroff, J. (2015) · Depression and Anxiety · doi:10.1002/da.22327 · Cited by 259
“[36–38] Mean depression scores were therefore converted to z scores, using the normative means and SDs from published research.[37,39,40] z Scores were calculated as z = M −μ σ , where M is the pre- or posttreatment mean for the HD sample, and μ and σ are the normative mean and SD.”
Methodde Zwart, P. L., Jeronimus, B. F., & de Jonge, P. (2019) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796018000227 · Cited by 189
Metadata
- Authors
- Zimmerman, M., Chelminski, I., & Posternak, M.
- Venue
- International Clinical Psychopharmacology
- Published
- 2004-01
- Volume
- 19
- Issue
- 1
- Pages
- 1-7
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2011349296
- Cited by
- 105
- References
- 10
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A review of studies of the Montgomery???Asberg Depression Rating Scale in controls: implications for the definition of remission in treatment studies of depression. https://app.cochat.ai/papers/10.1097/00004850-200401000-00001
- The paper
- Zimmerman, M., Chelminski, I., & Posternak, M. (2004). A review of studies of the Montgomery???Asberg Depression Rating Scale in controls: implications for the definition of remission in treatment studies of depression. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200401000-00001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.